In the future, we are planning to systematically review the level of evidence for the Ki-67 Index as a prognostic marker of response to chemo- and hormonotherapy in patients within ER+ tumor to identify patients who are most likely to benefit from chemotherapy. The gene discussed is MKI67; the disease is neoplasm.